Get the Stockscreener App
15.33
1.73%
-0.27
After Hours:
15.28
-0.05
-0.33%
Biodesix Inc stock is traded at $15.33, with a volume of 20,383.
It is down -1.73% in the last 24 hours and up +8.19% over the past month.
Biodesix Inc is a diagnostic solutions company with a focus on lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources: providing diagnostic testing services associated with blood-based lung and COVID tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties, as well as the development and commercialization of companion diagnostics.
See More
Previous Close:
$15.60
Open:
$15.95
24h Volume:
20,383
Relative Volume:
0.31
Market Cap:
$158.75M
Revenue:
$88.50M
Net Income/Loss:
$-35.27M
P/E Ratio:
-4.6519
EPS:
-3.2954
Net Cash Flow:
$-23.70M
1W Performance:
-0.20%
1M Performance:
+8.19%
6M Performance:
+94.05%
1Y Performance:
+166.33%
1-Day Range:
$15.04
$15.95
1-Week Range:
$14.79
$16.07
52-Week Range:
$5.00
$20.21
Biodesix Inc Stock (BDSX) Company Profile
Name
Biodesix Inc
Sector
Industry
Phone
303-417-0500
Address
919 WEST DILLON ROAD, LOUISVILLE
Compare BDSX vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BDSX
Biodesix Inc
|
15.33 | 161.55M | 88.50M | -35.27M | -23.70M | -3.2954 |
TMO
Thermo Fisher Scientific Inc
|
472.63 | 176.04B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
181.35 | 128.18B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
573.00 | 44.96B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
128.34 | 36.88B | 7.23B | 1.41B | 1.09B | 4.979 |
WAT
Waters Corp
|
360.54 | 35.13B | 3.77B | 449.25M | 240.68M | 7.8556 |
Biodesix Inc Stock (BDSX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-27-26 | Upgrade | William Blair | Mkt Perform → Outperform |
| May-14-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Sep-16-24 | Initiated | Scotiabank | Sector Outperform |
| Jul-26-24 | Initiated | Craig Hallum | Buy |
| May-13-24 | Initiated | TD Cowen | Buy |
| May-03-24 | Initiated | Lake Street | Buy |
| Nov-17-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-23-20 | Initiated | BTIG Research | Buy |
| Nov-23-20 | Initiated | Canaccord Genuity | Buy |
| Nov-23-20 | Initiated | Morgan Stanley | Overweight |
| Nov-23-20 | Initiated | William Blair | Outperform |
View All
Biodesix Inc Stock (BDSX) Latest News
BDSX Initiates Coverage On HC Wainwright & Co. -- Rating Set to Buy - GuruFocus
Are Medical Stocks Lagging Biodesix (BDSX) This Year? - Yahoo Finance
HC Wainwright Initiates Biodesix at Buy With $26 Price Target - marketscreener.com
Biodesix, Inc. (BDSX) reports Q1 loss, tops revenue estimates - MSN
BDSX Q1 2026 Earnings: EPS Beat on Lower-Than-Expected Loss; Stock Dips SlightlyLow Growth Earnings - newsline.com
BDSX Q1 2026 Earnings: EPS Surpasses Estimates Despite Net Loss, Stock Ticks DownEarnings Turnaround - newsline.com
Biodesix (BDSX) Tests Resistance After Modest Gain Amid Sector VolatilityVWAP Deviation - newsline.com
Biodesix Inc. (BDSX) Shows Resilience: Shares Gain 2.08% Amid Sector InterestAccumulation Line - newsline.com
Zacks Industry Outlook Highlights BrightSpring Health Services, Biodesix and HealthEquity - sharewise.com
BDSX News | BIODESIX INC (NASDAQ:BDSX) - ChartMill
Biodesix Q1 2026 Earnings: EPS Surprise Beats Estimates by 27.5% Amid Revenue Disclosure GapHigh Growth Earnings - newsline.com
[EFFECT] BIODESIX INC SEC Filing - Stock Titan
BDSX Stock Price, Quote & Chart | BIODESIX INC (NASDAQ:BDSX) - ChartMill
Biodesix Inc. (BDSX) Climbs 2% as Stock Tests Key Resistance Near $17.14Cumulative Volume - newsline.com
Biodesix Inc. (BDSX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Biodesix (NASDAQ: BDSX) registers resale of 375,000 shares - Stock Titan
Biodesix (BDSX) Gains 1.43% as Shares Test Resistance Near $17New Highs New Lows - The Legal Advocate
Are Medical Stocks Lagging Adicet Bio (ACET) This Year? - Yahoo Finance
BDSX Q1 2026 Earnings: EPS Exceeds Expectations Amid Ongoing Operational DevelopmentsQuarterly Financial Update - newsline.com
Wall Street Analysts Believe Biodesix (BDSX) Could Rally 104.29%: Here's is How to Trade - Zacks Investment Research
Biodesix Inc. (BDSX) Q1 2026 Earnings: Strong EPS Beat Overshadowed by Negative Stock ReactionFinal Results - newsline.com
Canaccord Lifts PT on Biodesix (BDSX) on Raised Revenue Assumptions - Insider Monkey
Biodesix (NASDAQ: BDSX) registers 375,000 shares for Perceptive resale - Stock Titan
Biodesix shareholders elect directors and approve executive compensation By Investing.com - Investing.com South Africa
Biodesix to Participate in Upcoming Investor Conferences - The Manila Times
Biodesix meets investors in Minneapolis, Chicago and Dana Point - Stock Titan
Biodesix shareholders elect directors and approve executive compensation - Investing.com India
Biodesix Shareholders Approve Directors and Governance Measures - TipRanks
Biodesix (NASDAQ: BDSX) holders back directors, pay and KPMG auditor - Stock Titan
Perceptive entities disclose 4.6% holding in Biodesix (NASDAQ: BDSX) - Stock Titan
Biodesix BDSX Q2 2025 Earnings Call Transcript - AOL.com
Biodesix Announces ATS 2026 Presentations Providing Real-World Clinical Evidence and Healthcare System Economic Value for Nodify Lung® Testing Strategy - The Manila Times
Blood test for lung nodules gets real-world spotlight at ATS 2026 - Stock Titan
BDSX Biodesix shifts focus to lung health diagnostics, CEO signals confidence in breakthrough testing pipeline despite sector volatility.Interim Report - The Legal Advocate
Does Biodesix (BDSX) have the potential to rally 103.33% as Wall Street analysts expect? - MSN
Biodesix (NASDAQ: BDSX) holder Soleus reports 416,599 shares (4.1%) - Stock Titan
Biodesix Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Q3 2025 Biodesix Inc Earnings Call Transcript - GuruFocus
Number of shareholders of Biodesix, Inc. – NASDAQ:BDSX - TradingView
Does Biodesix (BDSX) Have the Potential to Rally 103.33% as Wall Street Analysts Expect? - Yahoo Finance
Biodesix Earnings Call Signals Strong Growth Momentum - The Globe and Mail
Biodesix Faces Mounting Reimbursement and Enforcement Risks as Evolving Payer Policies Threaten Revenue Stability - TipRanks
TD Cowen Maintains Biodesix(BDSX.US) With Buy Rating, Maintains Target Price $30 - Moomoo
MSN Money - MSN
Canaccord Genuity Group Issues Positive Forecast for Biodesix (NASDAQ:BDSX) Stock Price - MarketBeat
Biodesix Inc Stock (BDSX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Biodesix Inc Stock (BDSX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| O'Kane Kieran | Chief Commercial Officer |
Feb 23 '26 |
Sale |
12.78 |
535 |
6,835 |
9,819 |
| Cowie Robin Harper | CFO, Sec'y & Treasurer |
Feb 23 '26 |
Sale |
12.78 |
535 |
6,835 |
16,231 |
| Vazquez Chris | Chief Accounting Officer |
Feb 23 '26 |
Sale |
12.78 |
211 |
2,696 |
1,586 |
| Hutton Scott | President & CEO |
Feb 23 '26 |
Sale |
12.78 |
1,490 |
19,036 |
48,767 |
0.56%
0.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):